Russell Investments Group Ltd. Grows Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Russell Investments Group Ltd. lifted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 4,810.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,745 shares of the company's stock after purchasing an additional 35,017 shares during the period. Russell Investments Group Ltd.'s holdings in Nurix Therapeutics were worth $673,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of NRIX. Vanguard Group Inc. grew its stake in Nurix Therapeutics by 8.3% in the fourth quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock worth $81,865,000 after purchasing an additional 333,452 shares during the period. Wellington Management Group LLP grew its stake in Nurix Therapeutics by 3.0% in the fourth quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company's stock worth $67,572,000 after purchasing an additional 104,500 shares during the period. Geode Capital Management LLC grew its stake in Nurix Therapeutics by 9.5% in the fourth quarter. Geode Capital Management LLC now owns 1,585,127 shares of the company's stock worth $29,870,000 after purchasing an additional 137,087 shares during the period. Nikko Asset Management Americas Inc. grew its stake in Nurix Therapeutics by 42.8% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after purchasing an additional 236,620 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in Nurix Therapeutics by 42.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after purchasing an additional 235,971 shares during the period.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX traded down $0.09 during midday trading on Monday, reaching $11.47. 784,359 shares of the company's stock traded hands, compared to its average volume of 895,565. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56. The stock has a 50 day moving average of $12.47 and a 200 day moving average of $18.27. The company has a market cap of $874.43 million, a price-to-earnings ratio of -3.97 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The company had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. During the same quarter in the prior year, the company earned ($0.76) earnings per share. Sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now owns 55,937 shares of the company's stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Houte Hans Van sold 2,811 shares of the firm's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the transaction, the chief financial officer now directly owns 39,549 shares in the company, valued at $785,047.65. This trade represents a 6.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,326 shares of company stock valued at $213,449. 7.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

NRIX has been the topic of several recent research reports. Leerink Partners initiated coverage on Nurix Therapeutics in a research note on Monday, March 17th. They issued a "market perform" rating and a $16.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Leerink Partnrs raised Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Royal Bank of Canada increased their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 29th. Finally, JPMorgan Chase & Co. cut their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Nurix Therapeutics has an average rating of "Moderate Buy" and an average target price of $30.44.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.